Skip to content
lennox

Partner Treatment Library

Sexual Health & ED Medications

Tadalafil / Sildenafil / Apomorphine RDT

A three-ingredient rapid-dissolve ED combination offered in three package counts.

Evidence brief in review

Common goals
Potential support for erectile response through PDE5 and central dopamine pathways.
Best program fit
May fit clinician-led ED care when the exact strengths, cardiovascular status, interactions, and safer single-agent alternatives are reviewed.
Format
Rapid-dissolve tablet · 6, 12, or 18 count

Partner education guide

Where this may fit in an offering.

Potential support for erectile response through PDE5 and central dopamine pathways. A rapid-dissolve format may feel convenient for selected individuals. May fit clinician-led ED care with clear maximum-use instructions and follow-up.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

  • Potential support for erectile response through PDE5 and central dopamine pathways.
  • A rapid-dissolve format may feel convenient for selected individuals.
  • Available package quantities are 6, 12, and 18 tablets.

Program value

How it may support a program

  • May fit clinician-led ED care with clear maximum-use instructions and follow-up.
  • Can support a broader sexual-health evaluation rather than treating ED as an isolated symptom.

The exact three-drug RDT is not FDA approved and has no product-matched efficacy trial. Combining ED agents may increase risk without adding benefit.

02 / Program fit

Program and operational considerations.

01Administration format
Catalog format: Rapid-dissolve tablet · 6, 12, or 18 count. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency
The screenshots show package quantities of 6, 12, and 18—not a dosing schedule. Use only at the clinician-prescribed interval and never infer frequency from package count.
03Expected duration
Use is generally reassessed based on erectile response, tolerability, cardiovascular safety, and whether underlying causes are being addressed.
04Practical considerations
May fit clinician-led ED care with clear maximum-use instructions and follow-up.

03 / Suitability considerations

Who may be considered.

Who may be considered

  • A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
  • An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

  • May fit clinician-led ED care with clear maximum-use instructions and follow-up.
  • Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

01

Common or temporary

  • Headache, flushing, nasal congestion, indigestion, dizziness, nausea, and visual color change may occur; tadalafil can also cause back pain or muscle aches.
  • Apomorphine can add nausea, vomiting, dizziness, sweating, sleepiness, or fainting. Combining active agents may intensify tolerability problems.

02

Serious or important

  • Severe low blood pressure, chest pain, priapism lasting more than four hours, sudden vision loss, sudden hearing loss, severe allergic reaction, or syncope requires urgent assessment.
  • Multiple PDE5 inhibitors have overlapping vasodilatory effects. Product labeling states that combination with other ED therapies has not been adequately studied.

03

Avoid or use only with specialist input

  • Any nitrate or nitric-oxide donor use, riociguat use, or sexual activity that is medically inadvisable because of cardiovascular status.
  • Unstable cardiovascular disease, recent major cardiac or neurologic event, severe hypotension, congenital long-QT syndrome or class IA/III antiarrhythmic use when vardenafil is present, or an unverified formula.

04

Screening checklist

  • Review cardiovascular fitness for sexual activity, blood pressure, nitrate and riociguat exposure, alpha-blockers, antihypertensives, CYP3A4 interactions, QT-risk medicines, kidney and liver status, eye or hearing history, and prior priapism.
  • Confirm every active strength, the maximum allowed use, package count, alcohol and recreational-drug use, and whether a simpler single-agent option is safer.

05

When to refer

  • Urgent care is appropriate for chest pain, fainting, severe hypotension, sudden vision or hearing change, or an erection lasting more than four hours.
  • Complex cardiovascular disease, unexplained ED, suspected endocrine disease, penile deformity, significant relationship or mental-health factors, or repeated treatment failure may require specialist evaluation.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Tadalafil and sildenafil have approved ED uses separately; the exact three-ingredient rapid-dissolve product has not been clinically validated.

01 / Human research

The clearest clinical signal

The PDE5 inhibitors have extensive separate ED evidence and sublingual apomorphine was studied in randomized trials. Combination benefit and absorption for this RDT remain unknown.

02 / Real-world reports

What people describe

People may value a rapid-dissolve format and 6-, 12-, or 18-tablet options, but should receive exact maximum-use and interaction instructions.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Additive vasodilation, nitrates, riociguat, alpha-blockers, cardiovascular disease, priapism, syncope, and rare vision or hearing events require careful review.

Does the research match this exact product?

No product-matched trial was identified for the exact tadalafil, sildenafil, and apomorphine RDT.

Research and regulatory context

Tadalafil and sildenafil each have ingredient-level ED evidence; older studies evaluated sublingual apomorphine separately. There is no product-matched trial establishing this compounded combination, strength, absorption, or net benefit.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Evidence brief in reviewReviewed sources are listed above

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments